AbbVie (MEX:ABBV) Tariff Resilience Score: 8/10 (As of Jul. 04, 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
71 GF Score
Price MXN4,402.62
GF Value MXN3,572.08
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Tariff Resilience Score?

AbbVie MEX:ABBV 71 Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 71/100 and a GF Value™ of MXN3,572.08 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, AbbVie ranks better than 99.61% on this metric.

AbbVie has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

AbbVie has AbbVie has a strong global presence with diverse manufacturing locations. Pharmaceuticals often have exemptions from tariffs, and AbbVie's pricing power and patent protections further mitigate risks. Historical impacts from tariffs have been limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AbbVie might have Highly Resilient.

AbbVie  (MEX:ABBV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AbbVie Tariff Resilience Score Related Terms

MEX:ABBV vs MRK, JNJ, AMGN: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AbbVie's Tariff Resilience Score falls into.


MEX:ABBV
71GF Score
AbbVie Inc MEX:ABBV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
AbbVie (MEX:ABBV) has a Tariff Resilience Score of 8 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AbbVie ranks #4 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is AbbVie's Tariff Resilience Score too high?
AbbVie's current Tariff Resilience Score is 8. Based on the distribution chart, AbbVie ranks #4 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AbbVie has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Tariff Resilience Score compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #4 out of 1030 companies for Tariff Resilience Score. This places AbbVie in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. AbbVie's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,572.08, compared to a current price of MXN4,402.62 — trading 23.3% above its estimated fair value. The current Tariff Resilience Score is 8. AbbVie's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,402.62 is trading 23.3% above its estimated GF Value™ of MXN3,572.08. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Tariff Resilience Score: 8
  • GF Value™: MXN3,572.08 vs. price of MXN4,402.62 (23.3% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
71GF Score

Get the complete analysis for MEX:ABBV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,402.62
Price
MXN3,572.08
GF Value